Status:
COMPLETED
Fecal Calprotectin Levels in Patients With Fibromyalgia
Lead Sponsor:
Ege University
Conditions:
Fibromyalgia
Irritable Bowel Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
This study was designed to evaluate fecal calprotectin levels in patients with fibromyalgia syndrome. Fecal calprotectin levels from fibromyalgia patients with and without gastrointestinal symptoms as...
Detailed Description
Fecal calprotectin (FC) is a calcium and zinc binding protein that is present in neutrophil granulocytes and is detected in the stool samples from subjects with inflammatory bowel disease and similar ...
Eligibility Criteria
Inclusion
- Groups 1 and 2: patients diagnosed as having Fibromyalgia syndrome according to American College of Rheumatology 2016 classification criteria (8). Group 3 will consist of healthy controls
- Older than 18 years of age
Exclusion
- Presence of gastrointestinal symptoms starting after the age of 50.
- Presence of inflammatory rheumatological disorder
- Presence of organic gastrointestinal disorder
- History of fever, infective gastroenteritis, endoscopy or colonoscopy in the previous month
- Family history of inflammatory bowel disease
- Patients with alarm symptoms that required further investigation such as weight loss, nocturnal diarrhea, rectal bleeding
- Illiteracy
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05404893
Start Date
April 1 2022
End Date
September 30 2022
Last Update
January 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ege University School of Medicine
Bornova, İzmir, Turkey (Türkiye), 35100